Skip to main content
. 2022 Apr 7;59(4):2002732. doi: 10.1183/13993003.02732-2020

FIGURE 3.

FIGURE 3

Antimicrobial peptides (AMPs) S100 calcium binding protein A8/S100 calcium binding protein A9 (S100A8/A9) and β-defensin 2 (BD2) (gene name DEFB4A) modulate the phagocytic capacity of human monocyte-derived macrophages (MDMs). Cells were pre-treated with indicated proteins or vehicle and the progression of phagocytosis of a) pHrodo Escherichia coli particles (gram-negative) and b) pHrodo Staphylococcus aureus particles (gram-positive) was monitored using the IncuCyte S3 Live-Cell Analysis System. For each time point, data are presented as a % of phagocytosis relative to respective vehicle control (100%, dotted horizontal line) (E. coli n=7, S. aureus n=4). The impact of the recombinant AMP on phagocytosis was calculated using a paired t-test; *: p<0.05; **: p<0.01; ***: p<0.001. c) Comparison of BD2, S100A8/A9 (S8/9) and BD2 co-treatment with S8/9 on phagocytic capacity of MDMs of pHrodo S. aureus particles at the 2 h time point. The impact of the recombinant AMP on phagocytosis was calculated using a paired t-test; ***: p<0.001. Differences between treatments were calculated with one-way ANOVA followed by Sidak multiple comparison test.